Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Breast-Milk enema: a natural boost for tiny babies?

NCT ID NCT07661992

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 5 times

Summary

This early-phase trial tests whether a small enema made from the mother's own breast milk can help very preterm infants (born before 28 weeks) pass their first stool (meconium). Delayed passage can slow feeding and raise the risk of serious gut infections. The study will enroll 20 infants and check safety, including any injury or infection, as well as how well the enema works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
breast milk
What this could lead to
If it works, this could offer a simple, natural way to help preterm infants pass their first stool, potentially reducing feeding delays and serious gut problems.
What could go wrong
This is a very early, small phase 1 trial with only 20 infants, so results may not apply widely. There are also risks like infection or rectal injury from the enema.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

23 to 28 weeks

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Preterm infants born at \>23 and \<28 weeks' gestational age born at Atrium Health Wake Forest Baptist Hospital or transferred in the first 24 hours of life. * postnatal age \>48 hours, absence of spontaneous passage of meconium by \>48 hours of life * availability of mother's own milk * written informed consent obtained from a parent or legal guardian. Exclusion Criteria: * Infants with Necrotizing Enterocolitis (NEC) ≥ stage II * spontaneous intestinal perforation (SIP) * gastrointestinal or anorectal malformations * infants that have developed severe hemodynamic instability or sepsis with need for vasoactive drugs * significant hematologic abnormalities such as neutropenia or thrombocytopenia. * Infants will also be excluded in the absence of written informed consent from a parent or legal guardian.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast milk are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.